Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
August 31, 2015 at 09:03 AM EDT
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has submitted a 505(b)(2) New Drug ...